Income statement
CAD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 40M | 34M | 26M | 18M | 1M |
| Gross Profit | 16M | 14M | 12M | 8M | 385K |
| Operating Income | 482K | 2M | 2M | -29K | -1M |
| EBITDA | 4M | 823K | 10M | -7M | -874K |
| Net Income | 562K | -2M | 8M | -9M | -1M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.10
+0.00% today
1Y Change
+25.00%
Window
Jun 23, 2025 → May 29, 2026
Coverage: 236 bars · Jun 23, 2025 → May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Delota Corp. (SYDRF) is a Healthcare stock with listed on OTC. The stock last traded around $0.10 and up 25.0% across the available one-year price window (Jun 23, 2025 → May 29, 2026). Baseline metrics include revenue growth of +18.0%, EPS growth of +126.3%, a dividend yield of 0.0%. What stands out right now is revenue +18.0%, EPS +126.3%, free cash flow +50.1% with operating margin -1.0% and ROIC -4.4%. Valuation is more restrained than many high-expectation growth names at price/sales 0.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SYDRF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SYDRF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SYDRF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SYDRF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.3M
-92.8% YoY
FY Net Income
-$1.3M
+85.2% YoY
Free Cash Flow
-$549.9K
-163.4% YoY
Revenue Growth
+18.0%
EPS Growth
+126.3%
Gross Margin
28.5%
Net Margin
-1.2%
Income statement
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 40M | 34M | 26M | 18M | 1M |
| Gross Profit | 16M | 14M | 12M | 8M | 385K |
| Operating Income | 482K | 2M | 2M | -29K | -1M |
| EBITDA | 4M | 823K | 10M | -7M | -874K |
| Net Income | 562K | -2M | 8M | -9M | -1M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2M | 2M | 1M | 1M | 298K |
| Total Assets | 15M | 14M | 15M | 13M | 1M |
| Total Liabilities | 14M | 13M | 13M | 22M | 2M |
| Shareholder Equity | 1M | 384K | 2M | -9M | -1M |
| Total Debt | 7M | 6M | 7M | 18M | 2M |
| Net Debt | 4M | 4M | 6M | 17M | 1M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
316K
-132.8% YoY
Capital Expenditures
234K
-137.9% YoY
Free Cash Flow
550K
-163.4% YoY
Key ratios
Gross Margin
28.5%
Operating Margin
-1.0%
Net Margin
-1.2%
ROE
-41.9%
Debt / Equity
7.72x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.